Prognostic value of cetuximab‐related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: Results from a randomized trial of the GERMAN AIO CRC Study Group
Sebastian Stintzing(Humboldt-Universität zu Berlin), Volker Heinemann(LMU Klinikum), Dominik Paul Modest(Berliner Hochschule für Technik), Andreas Jung(Ludwig-Maximilians-Universität München), Andreas Wollenberg(University Hospital Augsburg), Jens Neumann(German Cancer Research Center), Nicolas Moosmann(Praxis für Hämatologie und Onkologie), Clemens Gießen, Thomas Kirchner(Friedrich-Alexander-Universität Erlangen-Nürnberg), Rüdiger P. Laubender(Zimmer Biomet (Germany)), Christine Kapaun
Cited by 81
Related Papers
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
|New England Journal of Medicine|2016|2k
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2014|1.7k
Prognostic and Predictive Relevance of Primary Tumor Location in Patients With <i>RAS </i>Wild-Type Metastatic Colorectal Cancer
|JAMA Oncology|2016|722
β-Catenin Regulates the Expression of the Matrix Metalloproteinase-7 in Human Colorectal Cancer
|American Journal Of Pathology|1999|663